4D Molecular Therapeutics, Inc. FDMT 深 滬
等待開盤 09-18 09:30:00 美东时间
6.66
-0.030
-0.45%
華盛通- 最 高7.05
- 今 開6.72
- 成交量 42.03万股
- 最 低 6.64
- 昨 收 6.69
- 總市值 3.11亿
- 52周最高 11.125
- 市盈率 靜 --
- 換手率 0.90%
- 52周最低 2.235
- 委 比 69.44%
- 總股本 4670.25万
- 歷史最高 55.11
- 量 比 0.78
- 振 幅 6.13%
- 歷史最低 2.235
- 每 手 1
- 風險率 6.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) shares increased by 30.4% to $2.7 during ...
09-04 20:08
Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec'
Jim Cramer doesn't recommend buying more AppLovin stock. "Let's take a little off the table just to be prudent," he said.
09-03 19:46
4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness
4DMolecular Therapeutics announced the promotion of Julie Clark, M.D., to Chief Medical Officer and the addition of Liansheng Zhu, Ph.D., as SVP, Biometrics and Data Quality. The 4FRONT-1 Phase 3 trial is exceeding enrollment expectations, with completion now anticipated in Q1 2026. The company has also added distinguished retina industry advisors to enhance global development and commercialization expertise.
09-02 12:00
美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
08-13 09:10
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $25 Price Target
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $25 price target.
08-12 18:49
4D Molecular Therapeutics Q2 EPS $(0.98) Misses $(0.85) Estimate, Sales $15.000K Miss $374.143K Estimate
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.85) by 14.75 percent. This is a 55.56 percent decrease over losses of $(0.63) per
08-11 20:17
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics reported Q2 2025 financial results and operational highlights. Key updates include advancing the 4D-150 Phase 3 program in wet AMD with accelerated 4FRONT-1 data readout to H1 2027 and initiating 4FRONT-2 ahead of schedule. Positive 60-week results from the SPECTRA trial in DME were presented, showing favorable tolerability and sustained durability. The company streamlined its organization to drive late-stage execution, ...
08-11 12:00
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
4D Molecular Therapeutics announced that its management will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025, at 2:30 p.m. ET. An archived webcast will be available for one year on the company's "Investors" website. The company specializes in developing durable therapeutics, with its lead candidate 4D-150 targeting blinding retinal diseases, currently in Phase 3 for wet age-rela...
08-06 12:00
Market-Moving News for August 1st
FIG: 28% | Figma shares are trading higher on momentum following Thursday's IPO. COIN: -11% | Coinbase shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS and
08-01 19:15
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Apple Inc. (NASDAQ:AAPL) rose in pre-market trading as the company po...
08-01 18:56
